www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Abbott_Launches_Next_Generation_StarClose_R_SE_Vascular_Closure_System_726712ABBOTT PARK, Illinois, May 16 /PRNewswire/ --- New Device Designed to Provide Fast, Safe and Secure Vessel Closure Following Catheterization ProceduresAbbott today announced the launch of the StarClose(R) SE Vascular Closure System, a next-generation ...http://www.finanzen.net/nachricht/Abbott_Launches_Next_Generation_StarClose_R_SE_Vascular_Closure_System_726712http://www.finanzen.net/nachricht/Abbott_to_Present_Data_on_Novel_Cancer_Treatments_at_American_Society_of_Clinical_Oncology_Annual_Meeting_726696ABBOTT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Abbott scientists will highlight the latest clinical trial data of several investigative compounds in the company's oncology pipeline at this year's American Society of Clinical Oncology (ASCO) Annual ...http://www.finanzen.net/nachricht/Abbott_to_Present_Data_on_Novel_Cancer_Treatments_at_American_Society_of_Clinical_Oncology_Annual_Meeting_726696http://www.finanzen.net/nachricht/XIENCE_TM_V_Drug_Eluting_Stent_from_Abbott_Reduces_Major_Adverse_Cardiac_Events_in_Small_Vessel_Patients_Out_to_One_Year_725374BARCELONA, Spain, May 14 /PRNewswire/ --- Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small VesselsData presented today from an independent pooled subset analysis ...http://www.finanzen.net/nachricht/XIENCE_TM_V_Drug_Eluting_Stent_from_Abbott_Reduces_Major_Adverse_Cardiac_Events_in_Small_Vessel_Patients_Out_to_One_Year_725374http://www.finanzen.net/nachricht/XIENCE_TM_V_Drug_Eluting_Stent_from_Abbott_Outperforms_Market_Leading_Stent_in_Reducing_Major_Adverse_Cardiac_Events_at_Two_Years_724261BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE(TM) V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V ...http://www.finanzen.net/nachricht/XIENCE_TM_V_Drug_Eluting_Stent_from_Abbott_Outperforms_Market_Leading_Stent_in_Reducing_Major_Adverse_Cardiac_Events_at_Two_Years_724261http://www.finanzen.net/nachricht/XIENCE_TM_V_Drug_Eluting_Stent_from_Abbott_Outperforms_Market_Leading_Stent_in_Reducing_Major_Adverse_Cardiac_Events_at_Two_Years_724273BARCELONA, Spain, May 13 /PRNewswire/ --- Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUSLong-term data presented for the first time today ...http://www.finanzen.net/nachricht/XIENCE_TM_V_Drug_Eluting_Stent_from_Abbott_Outperforms_Market_Leading_Stent_in_Reducing_Major_Adverse_Cardiac_Events_at_Two_Years_724273http://www.finanzen.net/nachricht/Wissenschaftler_von_Abbott_stellen_neuen_Ansatz_zur_Behandlung_der_Aufmerksamkeitsdefizit_Hyperaktivitaetsstoerung_vor_722230ABBOTT PARK, Illinois, May 8 /PRNewswire/ --- Phase-II-Daten belegen, dass ABT-089, der am weitesten entwickelte NNR- Wirkstoffkandidat von Abbott, sich durch gute Sicherheit, Verträglichkeit und Wirksamkeit bei erwachsenen ADHS-Patienten auszeichnetAbbott ...http://www.finanzen.net/nachricht/Wissenschaftler_von_Abbott_stellen_neuen_Ansatz_zur_Behandlung_der_Aufmerksamkeitsdefizit_Hyperaktivitaetsstoerung_vor_722230http://www.finanzen.net/nachricht/New_Abbott_Study_of_Investigational_Vicodin_CR_TM_Meets_Primary_Efficacy_Endpoints_in_Phase_III_Trial_721987TAMPA, May 8 /PRNewswire-FirstCall/ -- New Phase III study data showed that Abbott's investigational hydrocodone bitartrate and acetaminophen (HC/APAP) extended release medicine reduced pain in patients with moderate to severe chronic low back pain, ...http://www.finanzen.net/nachricht/New_Abbott_Study_of_Investigational_Vicodin_CR_TM_Meets_Primary_Efficacy_Endpoints_in_Phase_III_Trial_721987http://www.finanzen.net/nachricht/Abbott_Scientists_Present_a_New_Approach_for_Treating_Attention_Deficit_Hyperactivity_Disorder_721230ABBOTT PARK, Illinois, May 7 /PRNewswire/ --- Phase II Data Demonstrate Abbott's Most Advanced NNR Candidate ABT-089 Shows Strong Safety, Tolerability And Efficacy in Adults With ADHDAbbott (NYSE: ABT) and other leading scientists will present new Phase ...http://www.finanzen.net/nachricht/Abbott_Scientists_Present_a_New_Approach_for_Treating_Attention_Deficit_Hyperactivity_Disorder_721230http://www.finanzen.net/nachricht/Abbott_Scientists_Present_a_New_Approach_for_Treating_Attention_Deficit_Hyperactivity_Disorder_721232ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott and other leading scientists will present new Phase II data showing that ABT-089, a selective neuronal nicotinic receptor (NNR) agonist, is a potentially effective and safe treatment for adults ...http://www.finanzen.net/nachricht/Abbott_Scientists_Present_a_New_Approach_for_Treating_Attention_Deficit_Hyperactivity_Disorder_721232http://www.finanzen.net/nachricht/Abbott_to_Present_at_Citi_Investment_Research_Global_Health_Care_Conference_721109ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott will present at the Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make ...http://www.finanzen.net/nachricht/Abbott_to_Present_at_Citi_Investment_Research_Global_Health_Care_Conference_721109